The Medicare Prescription Drug Rebate Rule The Medicare Part D prescription drug benefit provides our nation’s seniors with affordable drug coverage, which is more important now than ever. The rebate rule clumsily attempts to eliminate the primary tool used by
Court Ruling Finds that ERISA Preempts State PBM Law COURT REJECTS BID TO PREEMPT ERISA…In a unanimous decision, the U.S. Court of Appeals for the Tenth Circuit in PCMA v. Mulready court sustained PCMA’s challenge to four provisions in
JC Scott President & Chief Executive Officer JC Scott is the President and CEO of the Pharmaceutical Care Management Association (PCMA), the national association representing America’s pharmacy benefit managers, or PBMs. PBMs administer prescription drug plans for more than 275
This week, the U.S. Senate Health, Education, Labor & Pensions (HELP) Committee considers legislation that would lower choice in the market by creating a one-size-fits all pharmacy benefit contracting model for health plans and employers. As Congress considers mandating contracting
It seems that some have been tossing around the word fact lately when they really mean opinion. Facts are things that we have real evidence to support, not simply statements we want to be true. PBMs work to provide patients
With a nod to Dickens given that it’s the holidays, I’ve been thinking about biosimilars past, present and future lately. In that holiday spirit, even though the parallels aren’t perfect to the classic holiday story, let’s look at the biosimilar
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today released the following statement on the Congressional Budget Office’s (CBO) estimate that The INSULIN Act will increase taxpayer spending by approximately $23 billion over 10 years. Pharmacy benefit managers, PBMs,
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Biden Administration’s announcement to curb drug manufacturer patent abuses. “We applaud the Biden Administration for taking real action to reduce prescription
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today released a new report, “Drug Manufacturer Strategies for Keeping Drug Costs High,” on pharmaceutical industry pricing tactics that increase prescription drug costs for patients. The report, conducted by the research firm Visante,
PBMs Support and Encourage Biosimilar Competition Increased biosimilar competition drives down prescription drug costs Having multiple biosimilar and reference biologic competitor products with equivalent patient benefits on the market allows pharmacy benefit companies, PBMs, to push manufacturers to compete on
©2024 PCMA. All Rights Reserved.
